pepmg_

Study summary · research use only

Hyperandrogen-induced imbalance of FOXO4-AR regulatory loop contributes to ovulatory disorders in polycystic ovary syndrome

Study · Molecular therapy. Nucleic acids · 2025 · DOI 10.1016/j.omtn.2025.102543 · PMID 40520361

Plain-language summary

Paraphrased from the published abstract below — not a verdict on whether anything works.

This study examined the role of FOXO4 in polycystic ovary syndrome (PCOS) using granulosa cells from human patients with PCOS and a rat ovary model. The authors report decreased FOXO4 and CDKN1A expression and increased androgen receptor (AR) and CCND1 expression in granulosa cells from PCOS patients. Luteinizing hormone (LH) surge was associated with upregulated FOXO4 and CDKN1A and downregulated AR and CCND1 in vitro and in vivo; FOXO4 inhibited cell proliferation and cell cycle progression. Knockdown of FOXO4 in rat ovaries produced a PCOS-like model, and hyperandrogenism was linked to reduced FOXO4 expression in PCOS ovaries in vitro and in vivo. AR repressed FOXO4 expression by binding its promoter, while FOXO4 reduced AR protein levels via protease degradation, describing a regulatory loop disrupted by hyperandrogenism.

Abstract

Polycystic ovary syndrome (PCOS) is the leading cause of anovulatory infertility, and its underlying mechanisms remain largely unknown. Our study aimed to investigate the role of FOXO4 in PCOS and its possible regulatory mechanisms. Decreased FOXO4 and CDKN1A expressions and increased androgen receptor (AR) and CCND1 expressions were observed in granulosa cells (GCs) from patients with PCOS. Luteinizing hormone (LH) surge induced upregulation of FOXO4 and CDKN1A and downregulation of AR and CCND1 in vitro and in vivo. FOXO4 inhibited cell proliferation and cell cycle progression and partially mediated the induction of CCND1 and CDKN1A expressions by LH surge. Knockdown of FOXO4 in rat ovaries led to a PCOS-like model, and hyperandrogenism was responsible for reduced FOXO4 expression in ovaries of PCOS in vitro and in vivo. AR-mediated androgen action is known to play a key role in the development of PCOS. Notably, AR repressed FOXO4 expression by binding to its promoter, whereas FOXO4 inhibited AR protein levels through protease degradation, thus establishing a regulatory loop between AR and FOXO4 that was disrupted by hyperandrogenism. This study demonstrates that hyperandrogenism inhibits LH surge formation and disrupts the regulatory balance between FOXO4 and AR, which may contribute to the continued exacerbation of PCOS.

Read the full study on PubMed ↗ Open-access full text ↗

pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.